| Name | Title | Contact Details |
|---|
Dong Bang is a Santa Fe Springs, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Prospect Medical Holdings, Inc. is a leading provider of healthcare services comprised of 22 hospitals and over 140 primary and specialty care clinics located throughout Southern California, South Central Texas, Rhode Island, New Jersey, Connecticut, and Pennsylvania. Established in 1996, Prospect Medical Holdings, Inc. has grown into a significant provider of coordinated regional healthcare services throughout Southern California, South Central Texas, Rhode Island, New Jersey, Connecticut, and Pennsylvania. We were among the first healthcare providers in the country to adopt an operating model, termed Coordinated-Regional-Care, that prefigures the objectives of the Affordable Care Act – to improve quality, reduce cost and enhance overall patient care. Our comprehensive network aims to provide coordinated, personalized care. We specialize in building comprehensive networks of quality healthcare services designed to meet the needs of our patients and members. Our goal is always to ensure high-quality outcomes. Above all, we are committed to quality in all aspects of healthcare delivery, including: 1. Striving for the best possible patient outcomes 2. Maintaining the highest standards of patient safety 3. Acting with integrity at all times 4. Promoting open communication 5. Collaborating to better serve the healthcare needs of our communities
Welbi is the fastest-growing resident experience platform for senior living communities. Our software platform helps senior living communities boost their resident experience by streamlining administrative processes, personalizing their programming, and keeping them ahead of changing resident needs. Welbi`s assessment tools and real-time analytics help resident experience teams gain a deep and holistic understanding of their residents. Combined with our powerful planning tools, our solution guides teams to effectively deliver and evaluate their programming to create more engaging experiences, ultimately boosting their bottom line.
At Clinipace, a global, full-service contract research organization (CRO), our approach to clinical research is personal. We deliver a level of collaboration and flexibility not possible in a traditional CRO environment. Our personalized services and solutions, local regulatory expertise and therapeutic leadership are designed to face the most difficult industry challenges across all major therapeutic areas including oncology, gastroenterology, nephrology and urology. We strive to improve the way clinical research is performed and impact the future of health care using the most advanced technology and a CHALLENGE ACCEPTED approach. In April 2021, Clinipace & dMed merged creating a differentiated mid-size CRO with the largest Asia-Pacific presence. We are proud to have such a strong group of global investors focused on improving healthcare outcomes and giving sponsors a better CRO choice. dMed`s 2019 acquisition of Target Health commenced the process of building a Next Generation global CRO for biotech and pharmaceutical companies. Our investors have invested over $230M to build the next great global CRO. dMed`s acquisition of Target Health in 2019 began dMed`s evolution from a local to global CRO. Target Health LLC is owned by dMedClinical Co. Ltd., a privately held company that is majority owned, operated, managed, and controlled by a U.S. citizen and foreign entities located in the People`s Republic of China. Dr. Lingshi Tan, is the aforementioned U.S. citizen currently residing in Shanghai, China. Dr. Tan moved to Shanghai (from New York) to become Pfizer`s VP of Worldwide Development Operations, and Chairman and General Manager of Pfizer (China) Research & Development Co. Dr. Tan founded dMed in 2016 to satisfy the local demand for a high quality, responsive, flexible CRO.